Pediatric de novo movement disorders and ataxia in the context of SARS-CoV-2.

Nina-Maria Wilpert Ana Luisa de A Marcelino Ellen KnierimPasquale IncoronatoElisa Sanchez-Sendin Olga StaudacherAnne DrenckhahnPetra Bittigau Jakob Kreye Harald Prüss Markus Schuelke Andrea A Kühn Angela M Kaindl Marc Nikolaus

Published in: Journal of neurology (2023)

Infection with SARS-CoV-2 can trigger de novo MD in children. Most patients showed COVID-19-associated-ataxia and fewer-chorea. Our data suggest that patients benefit from immunosuppression, especially steroids. Despite treatment, one third of patients recovered only partially, which makes up an increasing cohort with neurological sequelae.

Keyphrases

sars cov
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
coronavirus disease
machine learning
respiratory syndrome coronavirus
early onset
artificial intelligence